Source MDx, Pfizer to ID Biomarkers for Cancer and Inflammatory Rx Response | GenomeWeb

Source MDx, Pfizer to ID Biomarkers for Cancer and Inflammatory Rx Response

Dec 27, 2007

NEW YORK (GenomeWeb News) — Molecular diagnostics company Source MDx today said it will work with Pfizer to uncover biomarkers linked to response and resistance to certain of the drug giant’s cancer and inflammatory candidate compounds.

As part of the multi-year alliance, the firms will use genomic and RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.